联合NSE水平及动力学、EEG和SSEP多模式评估心脏骤停后昏迷患者良好神经功能预后
该回顾性研究基于三级心脏骤停中心前瞻性登记,纳入2017年1月至2024年4月215例停镇静后昏迷且至少有一次EEG和24/48/72小时NSE测量的心脏骤停后患者,评估NSE、EEG和SSEP单独及联合预测3个月良好神经预后(CPC 1-2)的价值。3个月时54例(25.1%)预后良好。良好预后组NSE在24、48、72小时均显著低于不良预后组;NSE 24-72小时下降趋势预测良好预后PPV 82%、敏感性81%;良性EEG预测PPV 72%、敏感性94%;双侧N20基线波幅>0.85 µV预测PPV 75%、敏感性100%。NSE 48小时<51.5 µg/L、NSE下降趋势和良性EEG三者联合预测价值最佳(PPV 96%、敏感性76%)。
要点
- 心脏骤停后昏迷患者中,48小时NSE<51.5 µg/L预测3个月良好神经预后PPV 80%、敏感性93%;72小时NSE<41.5 µg/L预测PPV 83%、敏感性90%。
- NSE在24-72小时呈下降趋势高度预测良好预后,PPV 82%、敏感性81%。
- 良性EEG模式在良好预后组更常见(87.1% vs 14.9%,p<0.001),预测良好预后PPV 72%、敏感性94%。
- 双侧N20基线波幅>0.85 µV预测良好预后PPV 75%、敏感性100%。
- NSE 48小时<51.5 µg/L、NSE 24-72小时下降趋势和良性EEG三者联合预测价值最佳,PPV 96%、敏感性76%。
适用人群与场景
- 三级心脏骤停中心收治的心脏骤停后昏迷患者,停用镇静后纳入,且至少有一次EEG和24、48或/和72小时NSE血液测量。
诊断标准与关键阈值
- 良好神经预后定义为3个月时脑功能分类量表(CPC)1-2分。
- NSE正常定义为<17 µg/L。
- NSE 24、48、72小时预测良好预后的最佳截断值分别为<45.5、<51.5、<41.5 µg/L。
- SSEP双侧N20基线波幅>0.85 µV预测良好预后。
研究设计与关键结果
- 回顾性研究,基于前瞻性登记,纳入2017年1月至2024年4月215例心脏骤停后昏迷患者,年龄63岁(IQR 52-73),73%为男性。
- 3个月时54例(25.1%)预后良好。
- 良好预后组NSE显著低于不良预后组:24小时39(IQR 27-45)vs 54(IQR 37-82)µg/L,p<0.001;48小时26(IQR 18-43)vs 107(IQR 54-227)µg/L,p<0.001;72小时20(IQR 15-30)vs 184(IQR 60-300)µg/L,p<0.001。
- 24小时NSE正常(<17 µg/L)预测良好预后PPV 71%、敏感性9%。
- NSE 24、48、72小时最佳截断值分别<45.5、<51.5、<41.5 µg/L,PPV分别为64%、80%、83%,敏感性分别为74%、93%、90%。
- 24-72小时NSE下降趋势预测良好预后PPV 82%、敏感性81%。
- 良性EEG模式在良好预后组更常见(87.1% vs 14.9%,p<0.001),预测良好预后PPV 72%、敏感性94%。
- 双侧N20基线波幅>0.85 µV预测良好预后PPV 75%、敏感性100%。
证据类型、等级与局限
- 证据类型:回顾性研究(基于前瞻性登记)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在停镇静后的心脏骤停昏迷患者中,低NSE水平(24、48或72小时)、NSE随时间下降趋势、良性EEG和高N20波幅是良好神经预后的稳健标志物,可减少预后不确定性。
- NSE 48小时<51.5 µg/L、NSE 24-72小时下降趋势和良性EEG三者联合对良好预后预测价值最佳(PPV 96%、敏感性76%)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Prognostic markers of good neurological outcome after cardiac arrest (CA) remain limited. We aimed to evaluate the prognostic value of neuron-specific enolase (NSE), electroencephalogram (EEG) and somatosensory evoked potentials (SSEP) in predicting good outcome, assessed separately and in combination.
METHODS: A retrospective study was conducted in a tertiary CA center, using a prospective registry. We included all patients comatose after discontinuation of sedation and with one EEG and NSE blood measurement at 24, 48 or/and 72 h after CA. The primary outcome was favorable neurological outcome at three months, a Cerebral Performance Categories (CPC) scale 1-2 defining a good outcome.
RESULTS: Between January 2017 and April 2024, 215 patients were included. Participants were 63 years old (IQR [52-73]), and 73% were male. At 3 months, 54 patients (25.1%) had a good outcome. Compared to the poor outcome group, NSE blood levels were significantly lower in the good outcome group at 24 h (39 IQR[27-45] vs 54 IQR[37-82]µg/L, p < 0.001), 48 h (26 [18-43] vs 107 [54-227]µg/L, p < 0.001) and 72 h (20 µg/L IQR [15-30] vs 184 µg/l IQR [60-300], p < 0,001). Normal NSE (i.e., < 17 µg/L) at 24 h was highly predictive of good outcome, with a predictive positive value (PPV) of 71% despite a sensitivity (Se) of 9%. The best cut-off values for NSE at 24, 48 and 72 h were below 45.5, 51.5 and 41.5 µg/L, yielding PPV of 64%, 80% and 83% and sensitivities of 74%, 93% and 90%, respectively. A decreasing trend in NSE levels between 24 and 72 h was also highly predictive of good outcome (PPV 82%, Se 81%). A benign EEG pattern was more frequently observed in the good outcome group (87.1 vs 14.9%, p < 0.001) and predicted a good outcome with a PPV of 72% and a Se of 94%. Regarding SSEPs, a bilateral N20-baseline amplitude > 0.85 µV was predictive of good outcome (PPV 75%, Se 100%). The combination of NSE < 51.5 µg/l at 48 h, a decreasing NSE trend between 24 and 72 h and a benign EEG showed the best predictive value (PPV 96%, Se 76%).
CONCLUSION: In comatose patients after CA, a low NSE levels at 24, 48 h or 72 h, a decreasing trend in NSE over time, a benign EEG and a high N20 amplitude are robust markers of favorable outcome, reducing prognosis uncertainty.
参考来源
- Besnard A, Pelle J, Pruvost-Robieux E, et al. Multimodal assessment of favorable neurological outcome using NSE levels and kinetics, EEG and SSEP in comatose patients after cardiac arrest. Crit Care. 2025. PMID: 40217465. doi:10.1186/s13054-025-05378-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。